Keybanc has upgraded Thermo Fisher Scientific Inc (TMO) to Overweight from Sector Weight, reflecting a more optimistic outlook on the company's prospects. This upgrade, dated December 7, 2025, comes as TMO's current price stands at $572.25.
The move underscores a shift in analyst sentiment, which may indicate improved fundamentals or increased confidence in Thermo Fisher's strategic direction. With a market cap of $213.5 billion and a P/E ratio of 32.52, the company operates in the Life Sciences Tools & Services industry, providing a wide range of innovative products and services.
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, employs around 125,000 full-time staff. Its diverse offerings include reagents, instruments, and consumables used in various applications, such as biological and medical research, drug discovery, and diagnostic testing.
Upcoming earnings reports are anticipated on July 21, 2026, with an EPS estimate of $5.94 and revenue expected to reach $11.6 billion. This follows a solid performance in Q3 2025, where the company reported an EPS of $5.79, beating estimates by 4.4%. As analyst ratings can change over time, they should be viewed as one of many inputs in the investment decision-making process.